miR-101-3p sensitizes lung adenocarcinoma cells to irradiation via targeting BIRC5

Xin Meng1, Yanfei Sun2, Shiying Liu3

  • 1Department of Hyperbaric Oxygen, The First Affiliated Hospital of China Medical University, Liaoning, Shenyang 110001, P.R. China.

Oncology Letters
|March 18, 2021
PubMed

Insights

MicroRNA-101-3p acts as a tumor suppressor in lung adenocarcinoma (LUAD), enhancing radiotherapy sensitivity by targeting BIRC5. Low miR-101-3p expression correlates with poor LUAD prognosis, suggesting its therapeutic potential.

Area of Science:

  • Oncology
  • Molecular Biology
  • Radiotherapy Research

Background:

  • Lung adenocarcinoma (LUAD) is a leading cause of cancer mortality, with radiotherapy resistance hindering treatment success.
  • MicroRNA (miR)-101-3p is a known tumor suppressor in various cancers, including LUAD.
  • Understanding miR-101-3p's role in LUAD radioresistance is crucial for developing novel therapeutic strategies.

Purpose of the Study:

  • To investigate the function and mechanism of miR-101-3p in modulating radioresistance in lung adenocarcinoma cells.
  • To identify potential molecular targets of miR-101-3p involved in LUAD radioresistance.

Main Methods:

  • Bioinformatic analysis of Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) datasets.
  • In vitro assays including CCK-8, colony formation, immunofluorescence staining, caspase-3 activity, and western blotting.
  • Luciferase reporter assays to validate direct targeting of BIRC5 by miR-101-3p.

Main Results:

  • Downregulation of miR-101-3p in LUAD tissues correlated with poor patient prognosis.
  • Overexpression of miR-101-3p sensitized LUAD cells to ionizing radiation, reducing proliferation, colony formation, and DNA repair, while increasing apoptosis.
  • Baculoviral IAP repeat containing 5 (BIRC5) was identified as a direct target of miR-101-3p, and its increased expression abrogated the radiosensitizing effect of miR-101-3p.

Conclusions:

  • MiR-101-3p functions as a tumor suppressor that enhances LUAD cell sensitivity to radiotherapy.
  • The miR-101-3p/BIRC5 axis represents a potential therapeutic target for improving radiotherapy outcomes in LUAD patients.

Related Concept Videos